QQQ   272.85 (+0.36%)
AAPL   457.16 (+1.13%)
MSFT   209.25 (+0.03%)
FB   260.76 (+0.33%)
GOOGL   1,524.26 (+1.13%)
AMZN   3,205.09 (+1.36%)
NVDA   463.50 (+1.29%)
CGC   17.44 (+1.10%)
BABA   253.39 (-0.71%)
TSLA   1,607.64 (+3.40%)
GE   6.67 (-0.74%)
MU   46.66 (-3.75%)
AMD   82.47 (-0.17%)
T   30.02 (-0.53%)
F   7.14 (+0.42%)
ACB   9.69 (-1.12%)
GILD   68.33 (-0.74%)
NFLX   477.14 (+0.35%)
DIS   131.85 (+0.05%)
BAC   26.37 (-1.35%)
BA   177.79 (+1.34%)
QQQ   272.85 (+0.36%)
AAPL   457.16 (+1.13%)
MSFT   209.25 (+0.03%)
FB   260.76 (+0.33%)
GOOGL   1,524.26 (+1.13%)
AMZN   3,205.09 (+1.36%)
NVDA   463.50 (+1.29%)
CGC   17.44 (+1.10%)
BABA   253.39 (-0.71%)
TSLA   1,607.64 (+3.40%)
GE   6.67 (-0.74%)
MU   46.66 (-3.75%)
AMD   82.47 (-0.17%)
T   30.02 (-0.53%)
F   7.14 (+0.42%)
ACB   9.69 (-1.12%)
GILD   68.33 (-0.74%)
NFLX   477.14 (+0.35%)
DIS   131.85 (+0.05%)
BAC   26.37 (-1.35%)
BA   177.79 (+1.34%)
QQQ   272.85 (+0.36%)
AAPL   457.16 (+1.13%)
MSFT   209.25 (+0.03%)
FB   260.76 (+0.33%)
GOOGL   1,524.26 (+1.13%)
AMZN   3,205.09 (+1.36%)
NVDA   463.50 (+1.29%)
CGC   17.44 (+1.10%)
BABA   253.39 (-0.71%)
TSLA   1,607.64 (+3.40%)
GE   6.67 (-0.74%)
MU   46.66 (-3.75%)
AMD   82.47 (-0.17%)
T   30.02 (-0.53%)
F   7.14 (+0.42%)
ACB   9.69 (-1.12%)
GILD   68.33 (-0.74%)
NFLX   477.14 (+0.35%)
DIS   131.85 (+0.05%)
BAC   26.37 (-1.35%)
BA   177.79 (+1.34%)
QQQ   272.85 (+0.36%)
AAPL   457.16 (+1.13%)
MSFT   209.25 (+0.03%)
FB   260.76 (+0.33%)
GOOGL   1,524.26 (+1.13%)
AMZN   3,205.09 (+1.36%)
NVDA   463.50 (+1.29%)
CGC   17.44 (+1.10%)
BABA   253.39 (-0.71%)
TSLA   1,607.64 (+3.40%)
GE   6.67 (-0.74%)
MU   46.66 (-3.75%)
AMD   82.47 (-0.17%)
T   30.02 (-0.53%)
F   7.14 (+0.42%)
ACB   9.69 (-1.12%)
GILD   68.33 (-0.74%)
NFLX   477.14 (+0.35%)
DIS   131.85 (+0.05%)
BAC   26.37 (-1.35%)
BA   177.79 (+1.34%)
Log in

NASDAQ:CERSCerus Stock Price, Forecast & News

$6.85
-0.20 (-2.84 %)
(As of 08/13/2020 10:33 AM ET)
Add
Compare
Today's Range
$6.83
Now: $6.85
$7.11
50-Day Range
$6.52
MA: $6.87
$7.47
52-Week Range
$2.71
Now: $6.85
$7.56
Volume1.17 million shs
Average Volume1.94 million shs
Market Capitalization$1.14 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.29
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.
Read More
Cerus logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:CERS
CUSIP15708510
Phone925-288-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$74.65 million
Book Value$0.69 per share

Profitability

Net Income$-71,240,000.00

Miscellaneous

Employees240
Market Cap$1.14 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$6.85
-0.20 (-2.84 %)
(As of 08/13/2020 10:33 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CERS News and Ratings via Email

Sign-up to receive the latest news and ratings for CERS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cerus (NASDAQ:CERS) Frequently Asked Questions

How has Cerus' stock price been impacted by COVID-19?

Cerus' stock was trading at $4.76 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CERS stock has increased by 43.9% and is now trading at $6.85.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Cerus?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cerus
.

When is Cerus' next earnings date?

Cerus is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Cerus
.

How were Cerus' earnings last quarter?

Cerus Co. (NASDAQ:CERS) released its earnings results on Tuesday, August, 4th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01. The biotechnology company had revenue of $21.50 million for the quarter, compared to the consensus estimate of $21.50 million. Cerus had a negative net margin of 83.78% and a negative return on equity of 76.83%.
View Cerus' earnings history
.

What guidance has Cerus issued on next quarter's earnings?

Cerus issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, August, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $89-93 million, compared to the consensus revenue estimate of $112.8 million.

What price target have analysts set for CERS?

4 Wall Street analysts have issued twelve-month price targets for Cerus' stock. Their forecasts range from $6.50 to $9.00. On average, they expect Cerus' share price to reach $7.63 in the next twelve months. This suggests a possible upside of 11.3% from the stock's current price.
View analysts' price targets for Cerus
.

Has Cerus been receiving favorable news coverage?

Media stories about CERS stock have trended extremely negative recently, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cerus earned a news sentiment score of -4.1 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days.
View the latest news about Cerus
.

Who are some of Cerus' key competitors?

What other stocks do shareholders of Cerus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Opko Health (OPK), Immunomedics (IMMU), Advanced Micro Devices (AMD), Pfizer (PFE) and ACADIA Pharmaceuticals (ACAD).

Who are Cerus' key executives?

Cerus' management team includes the following people:
  • Mr. William M. Greenman, Pres, CEO & Director (Age 52)
  • Dr. Laurence M. Corash, Co-Founder, Chief Scientific Officer, Sr. VP & Corp. Director (Age 75)
  • Mr. Kevin D. Green, VP of Fin. & CFO (Age 47)
  • Ms. Chrystal N. Menard, Chief Legal Officer and Gen. Counsel (Age 48)
  • Dr. Richard J. Benjamin, Chief Medical Officer (Age 59)

What is Cerus' stock symbol?

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Who are Cerus' major shareholders?

Cerus' stock is owned by a variety of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (6.54%), Paradigm Capital Management Inc. NY (0.92%), Peregrine Capital Management LLC (0.88%), Raymond James & Associates (0.73%), Bank of New York Mellon Corp (0.43%) and Goldman Sachs Group Inc. (0.36%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, Timothy L Moore and William Mariner Greenman.
View institutional ownership trends for Cerus
.

Which institutional investors are selling Cerus stock?

CERS stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Paradigm Capital Management Inc. NY, Lesa Sroufe & Co, Premier Asset Management LLC, Raymond James & Associates, Macquarie Group Ltd., Personal CFO Solutions LLC, and Leap Investments LP. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, and William Mariner Greenman.
View insider buying and selling activity for Cerus
.

Which institutional investors are buying Cerus stock?

CERS stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, EAM Investors LLC, Sumitomo Mitsui Trust Holdings Inc., Goldman Sachs Group Inc., Bank of New York Mellon Corp, Swiss National Bank, Raymond James Financial Services Advisors Inc., and California Public Employees Retirement System. Company insiders that have bought Cerus stock in the last two years include Timothy L Moore, and William Mariner Greenman.
View insider buying and selling activity for Cerus
.

How do I buy shares of Cerus?

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cerus' stock price today?

One share of CERS stock can currently be purchased for approximately $6.85.

How big of a company is Cerus?

Cerus has a market capitalization of $1.14 billion and generates $74.65 million in revenue each year. The biotechnology company earns $-71,240,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Cerus employs 240 workers across the globe.

What is Cerus' official website?

The official website for Cerus is www.cerus.com.

How can I contact Cerus?

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.